Dermatology and Therapy (Jul 2024)

Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study

  • Tiago Torres,
  • Maria João Cruz,
  • Margarida Gonçalo,
  • Paulo Filipe,
  • Bruno Duarte,
  • João Alves,
  • José Miguel Alvarenga,
  • Gilberto Rosa,
  • Duarte Flor,
  • José Ramos,
  • Diogo Sousa,
  • Aureliu Rosca,
  • César Magalhães,
  • Cristina Claro,
  • Joana Rocha,
  • Catarina Vilarinho,
  • Fernando Mota,
  • Alberto Mota,
  • Maria João Paiva Lopes

DOI
https://doi.org/10.1007/s13555-024-01235-8
Journal volume & issue
Vol. 14, no. 8
pp. 2209 – 2221

Abstract

Read online

Abstract Introduction Several clinical trials have established the efficacy and safety of dupilumab for treating atopic dermatitis (AD). However, literature remains scarce in reporting the long-term effectiveness, safety, and drug survival of dupilumab in real-world settings. This study aimed to describe the latter outcomes of dupilumab in patients with AD. Methods This Portuguese, multicentric, observational, retrospective study included consecutive adult patients with AD who initiated dupilumab between January 2019 and September 2023, with a follow-up period up to 30 months. Drug discontinuation and adverse effects data were used to estimate drug survival. Clinical assessments included the Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), and Dermatology Life Quality Index (DLQI). Results A total of 312 patients were included in the study, with 56.4% being male (median age of 30 years, range 18–83). The 30-month drug survival rate was 82.0%. During the study period, 12.5% of the sample (n = 39 patients) discontinued treatment: 7.3% due to treatment failure, 2.9% due to safety concerns, 1.3% due to complete disease control, 0.6% due to pregnancy, and 0.3% due to lack of compliance. Adverse events not leading to drug discontinuation were noted in 25.6% of the sample (n = 80). Conjunctivitis was the most frequently reported adverse event (17%), followed by facial erythema (9%). At 30 months, the mean EASI decreased significantly from 27.30 ± 11.89 at baseline to 2.92 ± 3.96 (p < 0.001), reflecting an overall improvement of 89.3%. Similarly, pruritus NRS decreased from 7.36 ± 1.90 at baseline to 1.74 ± 2.16 at month 30 (p < 0.001), improving by 76.4%, and mean DLQI changed from 18.0 ± 7.09 at baseline to 2.67 ± 3.95 at month 30 (p < 0.001), decreasing by 85.2%. Conclusions This study increases our current understanding of dupilumab in real-world settings, demonstrating its long-term effectiveness and safety in treating AD.

Keywords